Prudentia Sciences Launches with $7M in Funding to Transform the Life Sciences Marketplace for Dealmaking
CAMBRIDGE, Mass.–(BUSINESS WIRE)– #AI–Prudentia Sciences Launches with $7M in Funding to Transform the Life Sciences Marketplace for Dealmaking
Read More
Montecito Medical Named Key Influencer in Healthcare Real Estate
NASHVILLE, Tenn.–(BUSINESS WIRE)–Once again, Montecito Medical has been named as a “Key Influencer in Healthcare Real Estate.” The national recognition came from the editors of Real Estate Forum and GlobeSt. Partners, who publish an annual list of influencers in specific areas of real estate that include healthcare, retail, industrial and multifamily housing. This marks the seventh consecutive year that the publication has named Montecito or its leadership as Key Influencers in the medical re
ATCC Announces Award from NCI to Support Research and Vaccine Development for Cancer and HIV
MANASSAS, Va.–(BUSINESS WIRE)– #CancerResearch–ATCC has been awarded a five-year, IDIQ contract by NCI to provide lab services to support AMRVS with research and vaccine development.
XiFin Celebrates National Pharmacist Day with Early Insights From 2025 Pharmacy Survey
SAN DIEGO–(BUSINESS WIRE)– #digitalpathology–XiFin, a leading provider of innovative healthcare revenue cycle management solutions that deliver artificial intelligence (AI)-enabled operational efficiency, interoperability, and simplicity, today previewed findings from its 2025 Pharmacy Transformation Outlook Survey, which highlights the growing role of pharmacists and the increasing interest in achieving operational efficiency through new technology and expanding pharmacy offerings via value-based care and spec
No-Cost Heart & Kidney Health Screenings Coming to Orlando to Detect Dangerous Type of Cholesterol You’ve Probably Never Tested For
ORLANDO, Fla.–(BUSINESS WIRE)– #ClinicalResearch–The Heart & Kidney Health Screening offers no-cost Lp(a) testing as well as screenings for other related metabolism and kidney risks.
Abdera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, today announced that Lori Lyons-Williams, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT in San Francisco, CA. Ms. Lyons will detail the company’s
New Data Reveals Critical Gaps in Health Plan Member Experience
CHICAGO–(BUSINESS WIRE)–Press Ganey, the leading provider of experience measurement, data analytics, and insights for health systems and health plans, has released its latest research report, “Health Plan Member Experience in 2024.” This report highlights critical areas for improvement in member experience, drawing on regulatory, voice-of-the-customer, and Press Ganey’s patient experience data. The findings underscore the pressing need for health plans to address barriers to higher member sat
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
DENVER–(BUSINESS WIRE)–TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Mode
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-8520, an investigational oral therapy for the treatment of adult patients with previously treated, KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC). BBO-8520 is designed to i
Syringe exchange fears hobble fight against West Virginia HIV outbreak
More than three years have passed since federal health officials arrived in central Appalachia to assess an alarming outbreak of HIV spread mostly between people who inject opioids or methamphetamine.